药群论坛

 找回密码
 立即注册

只需一步,快速开始

查看: 933|回复: 0
打印 上一主题 下一主题

EMA给印度无菌药品生产商的不符合报告

[复制链接]
跳转到指定楼层
楼主
aiyao 发表于 2017-9-19 13:47:47 | 只看该作者 回帖奖励 |倒序浏览 |阅读模式

马上注册,结交更多好友,享用更多功能,让你轻松玩转社区

您需要 登录 才可以下载或查看,没有帐号?立即注册  

x

26.07.2017

EMA non-compliance report on Indian manufacturer of sterile medicinal products

EMA给印度无菌药品生产商的不符合报告

Non-compliance reports are published in the EudraGMDP database of the European Medicines Angency (EMA) by European supervisory authorities. They refer to inspecti** inside as well as outside of the European Union. The non-compliance reports are independently submitted into the database by National Competent Authorities via a standardised form. For the company concerned, a non-compliance report has severe c**equences until the violati** are rectified. Amongst other things, a suspension of the marketing authorisation as well as recalls of the products in question could be mandated.

欧洲监管机构签发的不符合报告会发布在EMA的EUGMDP数据库中。其中列出了对欧盟内外场所实施的检查。不符合报告是由各国家药监机构通过标准格式上传至数据库的。对于受检公司来说,不符合报告会有严重的后果,直至违规行为被纠正。此外,受影响的药品上市许可可能会被搁置,产品可能会被召回。

On July, 5th 2017, the EMA published a non-compliance report on the Indian company Biocon Limited in Bangalore, which was inspected by the French supervisory agency "French National Agency for Medicines and Health Products Safety". During a pre-approval inspection, they observed 35 deviati** in 3 Biosimilar-products, 11 of which were major deviati** concerning the following topics:

2017年7月5日,EMA发布了一份印度公司BIOCON的不符合报告。该公司是由法规药监进行的药品批准前检查,检查中发现35项生物类似物缺陷,其中11项为主要缺陷,相关缺陷领域如下:

  • Environmental monitoring
  • 环境监测
  • Employee training
  • 员工培训
  • Handling of OOS results
  • OOS结果处理
  • Cleaning validation
  • 清洁验证
  • Process validation
  • 工艺验证
  • Supplier qualification
  • 供应商确认
  • Media Fill tests
  • 培养基灌装测试
  • Cross con**ination risks
  • 交叉污染风险
  • Batch records
  • 批记录
  • Handling of differential pressure alarms in classified areas
  • 不同洁净级别间的压差报警处理
  • Access management in SAP for batch release
  • 批放行用SAP管理权限问题

Alas, unlike in FDA warning letters, deficiencies aren't more closely specified. As a c**equence of this inspection, the 3 products will get no marketing authorisation until the deficiencies are corrected.

天啊,跟FDA警告信不一样,这些缺陷都没有进一步详细说明的。由于此次检测,缺陷纠正之前还不能获得3个产品的上市许可。

Source: EudraGMDP database of the EMA

来源:Julia


回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册  

本版积分规则

QQ|手机版|药群论坛 ( 蜀ICP备15007902号 )

GMT+8, 2024-11-1 11:28 AM , Processed in 0.082243 second(s), 18 queries .

本论坛拒绝任何人以任何形式在本论坛发表与中华人民共和国法律相抵触的言论! X3.2

© 2011-2014 免责声明:药群网所有内容仅代表发表者个人观点,不代表本论坛立场。

快速回复 返回顶部 返回列表